0.4703USD+20.59%Mkt Cap: 7.39M USDP/E: —Last update: 2026-05-26
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized Bi…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap7.39M USD
Enterprise Value82.66K USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-11.08M USD
Revenue/Share—
Last Price0.4703 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.56
PEG—
EV/EBITDA-0.01
EV/Revenue—
P/S—
P/B0.74
EPS (TTM)-1.45
EPS (Forward)-0.25
52W Range
0.28003% of range6.230
52W High6.230 USD
52W Low0.2800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-209.37%
ROA-119.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.27M USD
CapEx (TTM)5.88K USD
FCF Margin—
FCF Yield-98.59%
Net Debt-5.70M USD
Net Debt/EBITDA0.49
Balance Sheet
Debt/Equity0.07
Current Ratio1.81
Quick Ratio1.67
Book Value/Sh0.5250 USD
Cash/Share0.4070 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 7, 2016
Splits
Last Split1:16
Split DateJun 6, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)1.750 USD
Target Range1.500 USD – 2.000 USD
# Analysts2
Ownership
Shares Out.14.82M
Float14.04M
Insiders0.11%
Institutions5.33%
Short Interest
Short Ratio0.9d
Short % Float9.93%
Short % Out.9.91%
Shares Short1.02M
Short (prev mo.)662.21K
Technical
SMA 500.9046 (-48.0%)
SMA 2001.533 (-69.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.56M
Avg Vol (10d)1.34M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—